Leonard Zehr, Author at BioTuesdays

Feature

Cognetivity Neurosciences tackling dementia when it counts

Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF) is using artificial intelligence to enable early detection of cognitive decline in neurodegenerative disorders, such as dementia and Alzheimer’s disease, the leading...

June 1, 2021

Feature

Gregory Penner takes us into the world of aptamers

As president, a co-founder and CEO of closely-held NeoVentures Biotechnology, Gregory Penner, Ph.D., took a different route developing aptamers for healthcare solutions. His training was in quantitative genetics of crop...

May 25, 2021

Feature

Azura Ophthalmics taking dermatological approach to ocular surface diseases

Closely-held Azura Ophthalmics is developing the first ophthalmic keratolytics for the treatment of lid margin diseases, such as Meibomian gland dysfunction (MGD), blepharitis, dry eye disease and contact lens...

May 18, 2021

Feature

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

MiMedx Group (NASDAQ:MDXG) is forging ahead with its corporate turnaround as an industry leader in advanced wound care. “As a pioneer in amniotic tissue biologics, we have both a core business, focused on addressing the...

May 11, 2021

Feature

TransMedics redefining what’s possible in organ transplantation

TransMedics Group (NASDAQ:TMDX) is transforming the standard of care in solid organ transplants in order to increase the number of organ transplants and improve clinical outcomes.

May 4, 2021

Feature

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

As CEO of InfoBionic, a closely-held digital health company with an initial focus on cardiac arrhythmia detection and monitoring, Stuart Long knows his way around achieving commercial growth in the medical device market...

April 27, 2021

Feature

ViaCyte developing stem cell-derived islet replacement for diabetes

Closely-held ViaCyte, a company with two decades of experience, is utilizing pluripotent stem cell technology and novel delivery approaches to address multiple disease areas, with an initial focus and lead products...

April 20, 2021

Feature

Cyclacel translating cancer biology into potential medicines

Cyclacel (NASDAQ:CYCC) is developing several innovative therapies that target various phases of cell cycle control for the treatment of solid tumor and blood-borne cancers, such as leukemia.

April 13, 2021

Feature

Entasis Therapeutics targeting critical pathogens with precision antibiotics

Entasis Therapeutics (NASDAQ:ETTX) is developing a clinical and preclinical pipeline of potential first- and best-in-class targeted antibiotics to treat serious multidrug-resistant pathogens, with two assets in Phase 3...

April 6, 2021

Feature

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

As CEO of closely-held Nurx, the leading female-focused telehealth platform offering patients transparent pricing and judgment-free care, Varsha Rao brings decades of experience balancing mission-driven companies with a...

March 30, 2021

Author - Leonard Zehr

Cognetivity Neurosciences tackling dementia when it counts

Gregory Penner takes us into the world of aptamers

Azura Ophthalmics taking dermatological approach to ocular surface diseases

MiMedx’s proprietary tissue technology utilizing amniotic tissue as a platform for regenerative medicine

TransMedics redefining what’s possible in organ transplantation

Stuart Long outlines InfoBionic remote cardiac arrhythmia monitoring benefits

ViaCyte developing stem cell-derived islet replacement for diabetes

Cyclacel translating cancer biology into potential medicines

Entasis Therapeutics targeting critical pathogens with precision antibiotics

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

General

More